Pseudophakic cystoid macular edema
Related Experiment Video
Updated: May 27, 2026

Modeling Cataract Surgery in Mice
Published on: December 1, 2023
Yoshihiro Yonekawa1, Ivana K Kim
1Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA.
Purpose Of Review:
Pseudophakic cystoid macular edema (PCME) is a common cause of visual impairment after cataract surgery. This article systematically reviews and discusses the epidemiology, risk factors, diagnosis, and treatment of PCME, with a focus on advances in the past 1-2 years.
Recent Findings:
The incidence of PCME has declined with the advent of modern surgical techniques. Optical coherence tomography (OCT) has become an important adjunct to biomicroscopy and fluorescein angiography. PCME prophylaxis with topical nonsteroidal anti-inflammatory drugs remains unproven because long-term visual outcomes and comparative effectiveness studies are lacking. Chronic, refractory CME remains a therapeutic challenge, but investigational therapies with potential include corticosteroid intravitreal injections and implants, and intravitreal anti-vascular endothelial growth factor treatments. Few studies have assessed surgical options.
Summary:
There is currently a lack of well designed randomized clinical trials to guide the treatment of PCME.
Related Concept Videos
Glaucoma: Overview
Diabetic Retinopathy
Cerebral Edema ll: Pathophysiology
Photoreceptors and Visual Pathways
Cerebral Edema l: Introduction
Angle Closure Glaucoma: Treatment
